Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a single platform predict your risk for multiple chronic diseases?

NCT ID NCT07727915

Diagnosis Sponsor: Unidad de Investigación Genética Molecular Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 27, 2026 · Last updated Jul 28, 2026 · Updated 1 time

Summary

This pilot study is testing whether the ADEN platform can accurately identify people at risk for heart disease, respiratory problems, cancer, autoimmune conditions, and frailty. Researchers will compare the platform's risk ratings to those made by doctors. If it works, the platform could become a tool for early detection and prevention.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, the ADEN platform could provide a non-invasive way to detect early risk for multiple chronic diseases, enabling earlier interventions.
What could go wrong
This is a small pilot study (120 participants) focused on agreement with clinical assessment, not on health outcomes. The platform may not generalize beyond the Colombian population or meet the predefined success threshold.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 120 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Aug 2026

An estimate. Start dates often move.

Expected to finish

Nov 2026

An estimate. End dates often move.

Lead sponsor

A research network

The lead sponsor is a research network or cooperative group.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

General population that meets the conditions of the different subgroups

Ages

18 to 99 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

8.2 General Inclusion Criteria * Age ≥ 18 years. * Capacity to provide valid informed consent. * Availability to attend a baseline medical evaluation. * Acceptance of the clinical and analytical use of collected information, under confidentiality and data protection regulations (Law 1581/2012). * Meeting at least one specific criterion of the assigned subgroup. 8.3 Exclusion Criteria * Active acute illness (infectious, inflammatory, or chronic disease exacerbation) within the past 4 weeks. * Patients undergoing intensive active oncological treatment (chemotherapy, ongoing radiotherapy) at the time of recruitment. * Severe decompensation of autoimmune, respiratory, or metabolic disease. * Serious uncontrolled systemic disease limiting participation (advanced organ failure, terminal-stage neoplasm). * Confirmed or suspected pregnancy. * Severe cognitive or psychiatric disorder without a responsible caregiver for consent and follow-up. * Insufficient clinical information or inability to complete minimum protocol measurements. * Simultaneous participation in another clinical study that could interfere with result interpretation. * Refusal to participate or absence of informed consent.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Autoimmune are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

autoimmune disease cancer Respiration Disorders respiratory system disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Autoimmune Fragility Longevity Oncologic disease Preventive cardiology Respiration disorders

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • UNIGEM

    Medellín, Antioquia, 050021, Colombia

More trials for these conditions

Other studies related to the condition(s) this trial covers.